Merkel cell carcinoma drug, Bavencio, receives FDA approval

The U.S. Food and Drug Administration today granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy. This is the first FDA-approved treatment for metastatic MCC, a rare, aggressive form of skin cancer. ["]

The post Merkel cell carcinoma drug, Bavencio, receives FDA approval appeared first on Outbreak News Today.